Business Wire

AVANIA

16.3.2023 14:01:40 CET | Business Wire | Press release

Share
Avania Names MedTech Industry Veteran, Todd M. Pope, New Chairman of the Board

Avania, a leading, global medical technology contract research organization (CRO), today announced its appointment of Todd M. Pope as the new chairman of the board of directors. Todd brings 30 years of technology, medical device, and leadership experience across large cap and startup MedTech and was named to TIME Magazine’s 2018 list of 50 Most Influential People in Healthcare. Having spent the last 20 years in CEO roles in both private and public companies, he also currently serves as the chairman of the board of directors of AdvaMed ACCEL, the division within AdvaMed dedicated to addressing the unique needs of small and startup medical technology manufacturers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230316005199/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Avania Names Todd M. Pope New Chairman of the Board (Photo: Business Wire)

“I am very pleased to take on this role at such a dynamic time and support Avania on its growth journey,” said Pope. “After a rewarding career leading companies in the MedTech industry, I am motivated by the opportunity to work alongside the senior management team to execute on Avania’s transformational business strategy.”

Todd’s previous roles included global president of Johnson & Johnson Cordis, president and CEO of TransEnterix, as well as other senior executive positions within the MedTech space. Todd is currently director of the boards of Distalmotion and Humacyte, and a partner at Revival Healthcare Capital.

“Todd’s long history of leadership, coupled with his deep operating and commercial experience in the MedTech space makes him an ideal person for this role,” said Sapna Hornyak, president and CEO of Avania. “I look forward to working closely with Todd to ensure Avania continues to make a positive impact for all stakeholders, including Avania’s customers, our people, and the MedTech community. The senior management team along with the board of directors are excited about the future and look forward to bringing Avania to the next new phase with our new chairman.”

“We are very excited to be working with Todd,” added Edouard Pillot, managing partner, and Enrico Grasso, partner of Astorg Mid-Cap, which has majority interest in Avania. “He brings a wealth of MedTech industry experience and relationships that will provide invaluable connections with customers as well as insights into their evolving needs, and how Avania can best serve them. Todd’s leadership experience, with small and large businesses, will also support Avania as it grows and scales.”

About Avania

Avania is a leading, global full-service contract research organization focused on the management of clinical studies for medical devices, IVDs, biologics, and device-drug combination products internationally. Avania supports products from the first-in-human phase through the post-market phase with the same customized approach. When you need to advance your medical technology, it takes Avania. Avania’s vision is to be your trusted global partner in the evolution of your medical technology from innovation to commercialization to improving patient health and well-being.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230316005199/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bureau Veritas Strengthens Global Sustainable Finance Capabilities with Expanded Climate Bonds Approved Verifier Status26.3.2026 08:30:00 CET | Press release

Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), is pleased to announce the expansion of its geographical scope as an Approved Verifier under the Climate Bonds Standard and Certification Scheme. Additional offices in China, Japan, India, and France are now formally listed in the Climate Bonds Verifiers Directory. This expansion builds on Bureau Veritas’ established role since the approval of its Brazilian office in 2020, further enhancing its ability to support issuers with high-quality, independent verification services across key markets. “Our expanded presence as an Approved Verifier under the Climate Bonds Standard reinforces Bureau Veritas’ commitment to advancing credible, high‑integrity sustainable finance”, said Marc Roussel, Executive Vice President, Urbanization and Assurance at Bureau Veritas. “With verifier capabilities available across key markets, we continue to deliver local expertise with global assurance standards; boosting mark

Invivoscribe® Expands IVDR Portfolio with IdentiClone® Dx IGH Assay Certification26.3.2026 06:13:00 CET | Press release

IdentiClone® Dx IGH is the first IVDR-certified assay for the detection of clonal immunoglobulin gene rearrangements in patients with suspected B-cell lymphoproliferative disease. Invivoscribe, a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to announce that its IdentiClone Dx IGH Assay has received In Vitro Diagnostic Regulation (IVDR) 2017/746 Class C certification in the European Union (EU). Commercial availability of the IVDR-certified assay is anticipated by early April 2026. The IVDR replaces the former In Vitro Diagnostics Directive (IVDD), introducing significantly more stringent requirements for clinical evidence, performance evaluation, traceability, and post-market surveillance. Under IVDR, in vitro diagnostic devices are classified according to risk from Class A (lowest risk) to Class D (highest risk). Class C devices, such as IdentiClone Dx IGH, are considered high-risk tests that play a critical role in disease diagnosis an

Dominican Republic Drives Modernization of Electronic Passports Under the Leadership of the Thales - MIDAS Consortium25.3.2026 23:22:00 CET | Press release

The General Directorate of Passports, together with the Presidency of the Dominican Republic, are leading the transformation of the country’s passport issuance system with a new, secure, efficient document aligned with international standards.In 2025, the Thales-MIDAS consortium was awarded the contract to develop, issue, and personalize a modern, secure, and highly reliable travel document for Dominican citizens, incorporating additional cybersecurity measures. The Presidency of the Dominican Republic, through the General Directorate of Passports, issued the country’s first electronic passport as part of its strategy to modernize and strengthen national security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260324368065/en/ Passport of the Dominican Republic The new document was developed in partnership with Thales, world leader in advanced technologies for the Defense, Aerospace, Cybersecurity, and Digital sectors, and M

3D Systems Achieves Full-Scope EU MDR Certification, Accelerating European Launch of NextDent® Jetted Denture Solution Targeted for Summer 202625.3.2026 17:20:00 CET | Press release

Certification Marks Major Milestone in Strategic Dental Growth Initiative Addressing Straightening, Protection, Repair and Replacement of Teeth 3D Systems (NYSE: DDD) today announced it has received full-scope certification under the European Union Medical Device Regulation (EU MDR) 2017/745. The certification was attained on Monday, March 16, 2026. This milestone confirms that the Company’s quality system, technical documentation, and clinical evidence meet the most rigorous regulatory requirements in the medical device sector. With the MDR certificate in hand, 3D Systems will now introduce MDR-compliant product versions through a carefully coordinated, phased rollout across its dental product families and European markets. This approach ensures a smooth transition while maintaining uninterrupted product availability for customers and healthcare providers. The EU MDR certification immediately enables the introduction of innovative new materials and is a pivotal step for one of 3D Syst

Visa to Bring Privacy-Preserving Payments to Canton Network25.3.2026 17:00:00 CET | Press release

Visa is the first payments company selected to become a Super Validator on the Canton Network, where it will help banks and financial institutions bring new payment flows onchain Visa (NYSE:V), a global leader in digital payments, today announced it will join the Canton Network as the first major global payments company to serve as a Super Validator, to help extend privacy‑preserving blockchain infrastructure to banks and financial institutions around the world. Visa will be one of 40 Super Validators on Canton. That move goes straight to a core challenge for financial institutions: the same transparency that gives blockchains their appeal can clash with privacy expectations financial institutions operate under. Canton Network, a blockchain built for regulated finance, has privacy built in from the beginning, so organizations can use shared infrastructure without exposing sensitive information. As a Super Validator, Visa will help clients who choose to run and secure operations on the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye